Recovery in infection-related products other than COVID-19
First written in FY2024-Q3. 2 of 5 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026.
The whole theme swung hardest in 2019: 2 of 6 companies on the "Worse" side.
1 other company's latest entry also says "Other".
- FY2026Full-year decline in reagents for microbiological testingAnnual report
「By product, sales of reagents for microbiological testing were ¥4,284 million, down 4.8% year on year.」
From the period in which recovery in products such as rapid diagnostic kits and contributions from new products were reported, full-year sales of reagents for microbiological testing declined 4.8% year on year. - FY2026-H1Decline in reagents for microbiological testingAnnual report
「By product category, sales of reagents for microbiological testing were ¥2,148 million, down 2.1% year on year.」
Reagents for microbiological testing, including infectious disease-related products other than those for COVID-19, which had recovered and increased in the previous period, declined 2.1% year on year. - FY2025AdvancedAnnual report
「By product, sales of reagents for microbiological testing increased to ¥4,501 million, driven by higher sales of rapid diagnostic kits, up 4.4% year on year.」
For infectious disease-related products other than those for COVID-19, growth in rapid diagnostic kits resulted in full-year sales of ¥4,501 million, up 4.4% year on year. - FY2025-H1AdvancedAnnual report
「Sales of new rapid diagnostic kits, “ImmunoCatch–StrepA” and “ImmunoCatch–Adeno,” increased, bringing microbiological testing reagents to ¥2,194 million, up 3.0% year on year.」
For products related to infectious diseases other than COVID-19, growth in sales of the rapid diagnostic kits ImmunoCatch–StrepA and ImmunoCatch–Adeno was newly disclosed in specific terms. - FY2024-Q3First statedAnnual report
「Reagents for microbiological testing increased 9.6% year on year to ¥3.339 billion, reflecting a significant recovery in products related to infectious diseases other than COVID-19, particularly rapid diagnostic kits and reagents for antimicrobial susceptibility testing.」
The recovery in products related to infectious diseases other than COVID-19, particularly rapid diagnostic kits and reagents for antimicrobial susceptibility testing, was disclosed for the first time as a separate performance factor.